0 items USD 0.00Top 6 Therapeutic Companies to Look out for Acute Renal Failure (Acute Kidney Injury)
According to Report forecasts, total incident population of Acute Kidney Injury in 7 major markets was estimated to be 1.5 Million in 2016.
Acute kidney disease has consistently been associated with increased morbidity and mortality and multiple studies, as well as a recent meta-analysis, have demonstrated worse outcomes in the case of hospitalized patients.
Acute renal failure (ARF) is characterized by azotemia that progresses over several hours or days, with or without oliguria. Acute kidney injury (AKI), formerly called acute renal failure (ARF), is commonly defined as an abrupt decline in renal function, clinically manifesting as a reversible acute increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to abrupt loss of kidney function, leading to the retention of waste products, electrolyte disturbances, and volume status changes.
ARF is further sub-classified into three stages: Stage-I, Stage- II and Stage- III. Out of the three main stages, Stage II ARF has the highest percentage of incidence. Based on DelveInsight鈥檚 analysis, approximately 36% of Acute Renal Failure patients suffered Stage II ARF, 35% suffered Stage III ARF and 28% suffered Stage I ARF in 2016.
According to report鈥檚 assessment for the 麻豆原创 Size suggests that owing to the launch of upcoming therapies, an increase of the Global market size (7MM and Rest of the world) of Acute Renal Failure during the study period (2016-2027) can be observed. Also, as per DelveInsight鈥檚 estimation, the 7MM 麻豆原创 Size of Acute Renal Failure is expected to reach up to USD 8.7 billion in the year 2027.
There is large windows of opportunity: to prevent AKI, to treat AKI after its onset, and to halt progression to ESRD. The pharmaceutical industry are investing on clinical trials conducted in the cardiovascular space, yet is little reluctant to enter the kidney market as the overall market is driven by monitoring system followed by transplantation with a very small therapeutic window. Some of the flaws in clinical trial design contributing to poor outcomes and potential strategies for designing clinical trials for AKI have been realized.
Many novel therapies are under the later phase of development targeting a better preventive and therapeutic approach. Few听Acute Renal Failure (ARF) (Acute Kidney Injury)听Pipeline Products听 given below:
Analysts estimate that the market is expected to show a significant rise, mainly attributed to the launch of emerging therapies in coming years.
1. Quark Pharma:听QPI-1002, an siRNA targeting the p53 gene: clinical trials include a Phase I/ II study for the prevention of Delayed Graft Function (DGF) in deceased donor kidney transplant patients, and two Phase I studies in Acute Kidney Injury (AKI) following cardiac surgery. The drug has received Orphan Drug Designation from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and Fast Track designation by the FDA for the DGF indication.(Source: Company Website)
2.听AM Pharma:AM鈥怭harma B.V. focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, company got positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney Injury (AKI), the largest therapeutic study in AKI to date.(Source: Company Website)
3.Angion Biomedica:听BB3 is a small molecule with hepatocyte growth factor (HGF)-like activity that is entering Phase 3 clinical trials to limit delayed graft function in kidney transplant recipients, and entering Phase 2 clinical trials in cardiac surgery patients who develop acute kidney injury.听(Source: Company Website)
4.听LG Life Sciences:听Gemigliptin is a new member of this family of drugs, and studies have revealed certain advantages of gemigliptin use compared to its previous congeners. Besides, this drug has also been studied for the treatment of T2DM as monotherapy, in combination with metformin or other oral antidiabetic drugs and in T2DM with moderate-to-severe renal failure(Phase II/III Acute kidney injury).
5.Alloksys :听Alloksys Life Sciences developed the therapeutic 搁贰厂颁础笔庐 platform based on Alkaline Phosphatase (AP), a naturally occurring protein in the human body. 搁贰厂颁础笔庐 further protects, maintains and restores integrity of physiological barriers, such as Kidney Glomerulus Barrier (KGB) Blood Brain Barrier(BBB), Lung Alveolar Barrier(LAB), Gut Barrier (GB) and Placental Barrier (PB).(Source: Company Website)
6.听Exponential Biotherapeutics:听EBI鈥檚 lead product suppresses the exaggerated immune response and therefore has the potential to prevent a range of severe inflammatory disorders. The most important indication is acute kidney injury (AKI).After successful development of EBI鈥檚 lead product (EA-230) for AKI and irradiation damage, EBI鈥檚 pipeline provides a path forward for the development of new and promising critical care therapies for multiple organ damage related to systemic inflammatory responses.(Source: Company Website)
听
Related Pharmaceutical Industry Articles
1. Global Pharmaceuticals 麻豆原创 Forecast: Drivers, Value Chain Analysis & Trends
2. World鈥檚 Top 10 Pharmaceutical Companies by Revenue
3. U.S. Top 10 Pharmaceutical Companies by 麻豆原创 Turnover
4. World's Top Selling Pharmaceutical Drugs and Manufacturers by Sales
5. Top 15 Pharma Companies in India
听
Email a colleague
Printer version
Send by email
听
About The Author
Sudeep Chakravarty
